CUREVAC N.V. news, videos and press releases - Page 4
For more news please use our advanced search feature.
CUREVAC N.V. - More news...
CUREVAC N.V. - More news...
- EQS-News: CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
- CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
- EQS-News: CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
- CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
- EQS-News: CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
- CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
- EQS-News: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
- CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
- EQS-News: CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
- CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
- EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
- EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
- CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
- EQS-News: CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
- CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
- DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
- DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
- CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
- CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
- DGAP-News: CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
- CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
- DGAP-News: CureVac Announces Voting Results of General Meeting
- CureVac Announces Voting Results of General Meeting
- DGAP-News: CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
- DGAP-News: CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen
- CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
- CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
- DGAP-News: CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
- DGAP-News: CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
